Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 11/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283855 | 0.92 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6285997 | 0.79 | GRM1 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6279750 | 0.77 | GRIN1 (0.39) | — | |
| SCHEMBL6284962 | 0.75 | MIF (0.35) | CYP11B2 | |
| SCHEMBL6284455 | 0.74 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6280176 | 0.74 | CTSD (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3996861 | 0.69 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2643457 | 0.66 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3997669 | 0.64 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21116203 | 0.63 | USP8 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887885-B2 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | MERCK SHARP & DOHME LTD | 2005-05-03 | — | — | US | claimed |
| US-6887885-B2 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | MERCK SHARP & DOHME LTD | 2005-05-03 | — | — | US | disclosed |
| US-20040132767-A1 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132767-A1 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | GABRA1, GABRA2, GABRA3 | GABRA1 1/4885GABRG2 21/4885GABRB3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.